ArticleScience progress
Clinical value of the lactate-to-albumin ratio in assessing prognosis in critically ill patients with sepsis-associated encephalopathy: A retrospective analysis.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectiveSepsis-associated encephalopathy (SAE) is a critical complication of sepsis with high mortality, yet reliable prognostic biomarkers remain limited. This study aimed to investigate the association between the lactate-to-albumin ratio (LAR) and short- and long-term mortality in SAE patients.MethodsA retrospective cohort analysis was conducted using the MIMIC-IV database, including 874 adult SAE patients. LAR was calculated within 24 h of ICU admission. Participants were stratified into quartiles (Q1-Q4) based on LAR values. Cox proportional hazards models and restricted cubic spline (RCS) were employed to evaluate relationships between LAR and mortality at 30, 90, 180, and 365 days. The area under the receiver operating characteristic (ROC) curve (AUC) was employed to evaluate the predictive performance of LAR.ResultsKaplan-Meier analysis demonstrated that, the Q2,Q3,Q4 group experienced significantly lower survival rate compared to the Q1 group for 30-day, 90-day, 180-day, and 365-day, with the Q4 group had the lowest survival rate. Cox proportional hazards regression revealed LAR as a robust independent predictor, demonstrating persistent prognostic significance across all observed time points. RCS analysis revealed a nonlinear association between LAR and the mortality of SAE. The ROC curves demonstrated robust predictive ability of LAR, with AUCs of 0.753 (30-day), 0.736 (90-day), 0.733 (180-day), and 0.725 (365-day).ConclusionsLAR serves as an easily accessible, independent prognostic biomarker for predicting short- and long-term mortality in SAE patients, exhibiting a distinct nonlinear correlation with mortality risks over these periods. These results underscore its potential value in risk stratification and in guiding early clinical interventions. Additional prospective studies are needed to confirm its role in the management of SAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.